European Medicines Agency studying the need for COVID-19 booster dose
Category: #health  | By Nikita Chaurasia  | Date: 2021-09-08 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

European Medicines Agency studying the need for COVID-19 booster dose

The European Medicines Agency has advanced the evaluation on the need to recommend a booster dose of the COVID-19 vaccine made by Pfizer-BioNTech.

The EU drug regulator stated that it is considering the necessity of the third dose of the vaccine six months after the first two doses, to people aged 16 and above, to restore protection after its efficacy decreases.

EMA's experts are expediting the assessment of the data submitted by Pfizer and BioNTech, involving details of the results from a present trial in which around 300 healthy adults were given a booster shot six months after their second dose.

Pfizer has already applied for authorization of a third dose to the U.S. Food and Drug Administer and the U.S. government stated last month that the booster doses would mostly be available by the end of September.

Meanwhile, Israel has already begun administering boosters and the plan is under consideration in other countries that have vulnerable populations, including Germany and France.

The Amsterdam-based EMA mentioned that it anticipates deciding whether or not to advise a third dose of the Pfizer vaccine in the coming weeks. It stated that it was also examining the use of a third dose of the coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna in people having weak immune systems, suggesting a need for an extra dose as a part of their primary vaccination programs.

It is to be noted that the World Health Organization has requested rich countries not to use booster doses at least until September end, as it is not yet scientifically proven that the shots are necessary. It stated that COVID-19 vaccines should be used in developing countries that have received less than 2% of over 5 billion doses administered.

Many studies have indicated that protection provided by authorized coronavirus vaccines against the highly infectious delta variant decreases months after people have been immunized, however, the shots continue to offer strong protection against severe complications, hospitalization, and death.

Source Credits –

https://www.business-standard.com/article/current-affairs/eu-regulator-evaluating-if-covid-19-vaccine-booster-dose-is-needed-121090601203_1.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...